It is estimated that as many as 45 million people may be at risk of anaphylaxis from food, drugs, and/or insect stings. 1 Anaphylaxis is defined as a serious allergic reaction that is rapid in onset and could result in death. 2,3 The exact incidence of anaphylaxis has not been established and there is no comprehensive source regarding its epidemiology. A recent retrospective cohort study suggested that the risk of anaphylaxis is increasing in the US. 2 This trend is consistent with epidemiologic reports internationally. 4 The drug of choice in emergent anaphylactic situations is epinephrine, often in conjunction with a myriad of other drugs. 5EpiPen and EpiPen Jr (0.3-and 0.15-mg epinephrine, respectively; Mylan Specialty Inc.) autoinjectors are FDA approved for emergency treatment of anaphylaxis. The manufacturer reports that approximately 1 accidental injection occurs per 50,000 units dispensed; however, these events are likely underreported. 6 This is best exemplified through studies examining self-administration techniques, with only 30-44% of patients being able to correctly demonstrate how to use their EpiPen device. 7-10 This has resulted in the development of a newer generation of epinephrine autoinjector, Intelliject's Auvi-Q. Part of the impetus for the introduction of this product was
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.